Last updated: 2026-09-16 12:38:20. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Rocket Pharmaceuticals, Inc. (RCKT) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $3.64, with a market capitalisation of $376.53M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $2.53 to $5.45. This page covers its latest market performance, valuation, price trends and company information.
$376.53M | |
$3.36 | |
$67.48 | |
$2.19 | |
$3.41 | |
99.21K | |
1.97M | |
-- | |
$5.45 | |
$2.53 | |
-- | |
-- |
Rocket Pharmaceuticals, Inc. (RCKT) is trading at $3.64 in pre-market trading as of 2026-09-16 12:37:00, up 6.74% ($0.23) from the previous close of $3.41
Pre-market trading shows how investors are pricing RCKT before the regular session opens. The current pre-market price is above the previous close, indicating positive early trading sentiment.
Over the past seven days, Rocket Pharmaceuticals, Inc. (RCKT) moved from $3.86 to $3.64, representing a decline of 5.70% ($0.22).
The stock traded between $3.21 and $3.88 during the period. The latest price is near the middle of the 7-day range, indicating strong downward.
The average daily volume was 1.47 million shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 38.0%
RCKT is currently trading at $3.64, placing it 38.0% of the way from its 52-week low of $2.53 to its 52-week high of $5.45. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. It has one reportable segment related to R&D and commercial readiness of its gene therapies.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 202 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Rocket Pharmaceuticals, Inc. (RCKT) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.